OptimizeRx Co. (NASDAQ:OPRX) Shares Sold by Blair William & Co. IL

Blair William & Co. IL reduced its holdings in OptimizeRx Co. (NASDAQ:OPRX) by 17.7% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 643,757 shares of the company’s stock after selling 138,816 shares during the quarter. Blair William & Co. IL owned approximately 3.52% of OptimizeRx worth $6,438,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. Millrace Asset Group Inc. purchased a new position in OptimizeRx during the fourth quarter worth approximately $1,917,000. G2 Investment Partners Management LLC raised its position in shares of OptimizeRx by 26.0% in the 4th quarter. G2 Investment Partners Management LLC now owns 468,120 shares of the company’s stock worth $6,699,000 after buying an additional 96,646 shares during the period. Greenwood Capital Associates LLC boosted its holdings in OptimizeRx by 58.8% in the fourth quarter. Greenwood Capital Associates LLC now owns 54,675 shares of the company’s stock valued at $782,000 after acquiring an additional 20,245 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. purchased a new stake in OptimizeRx during the first quarter valued at about $542,000. Finally, BNP Paribas Financial Markets increased its stake in OptimizeRx by 283.6% during the first quarter. BNP Paribas Financial Markets now owns 27,910 shares of the company’s stock worth $339,000 after acquiring an additional 20,634 shares during the last quarter. 76.47% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the company. B. Riley began coverage on OptimizeRx in a research note on Thursday, July 25th. They issued a “buy” rating and a $18.50 price objective on the stock. Barclays decreased their price objective on shares of OptimizeRx from $15.00 to $11.00 and set an “equal weight” rating for the company in a research note on Monday, August 12th. Royal Bank of Canada decreased their price target on shares of OptimizeRx from $17.00 to $14.00 and set an “outperform” rating for the company in a research report on Friday, August 16th. Finally, JMP Securities reissued a “market outperform” rating and issued a $16.00 price objective on shares of OptimizeRx in a research report on Friday, June 21st. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, OptimizeRx has a consensus rating of “Moderate Buy” and a consensus price target of $14.50.

OptimizeRx Trading Up 0.3 %

NASDAQ:OPRX opened at $7.88 on Friday. The stock has a market cap of $144.36 million, a price-to-earnings ratio of -7.73 and a beta of 1.27. OptimizeRx Co. has a one year low of $6.92 and a one year high of $16.65. The company has a debt-to-equity ratio of 0.27, a quick ratio of 3.07 and a current ratio of 3.07. The business’s 50-day simple moving average is $8.87 and its 200 day simple moving average is $10.54.

OptimizeRx (NASDAQ:OPRX) last announced its earnings results on Thursday, August 8th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.11. The company had revenue of $18.81 million for the quarter, compared to analyst estimates of $20.47 million. OptimizeRx had a negative return on equity of 5.97% and a negative net margin of 21.53%. As a group, sell-side analysts predict that OptimizeRx Co. will post -0.33 earnings per share for the current fiscal year.

OptimizeRx Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.